...
首页> 外文期刊>European journal of gynaecological oncology >Sequencing of SMAD4 somatic variation in patients with serous ovarian cancer
【24h】

Sequencing of SMAD4 somatic variation in patients with serous ovarian cancer

机译:浆液癌患者SMAD4体细胞变异的测序

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: A previous study has indicated SMAD4 mutations identified in patients with serous ovarian cancer. The aim of study is to analyze the SMAD4 mutation in Chinese people with primary serous ovarian cancer and attempt to build the correlation between the genotype and clinical phenotype or parameters of clinical pathological; thus to explore the precise general theory for individual treatment of serous ovarian cancer. Materials and Methods: The authors collected 90 serous ovarian cancer cases with primary samples that were identified by pathologist. DNA was extracted from parafim-embedded tumor tissues. The exon 2, 8, 9 and 11 of SMAD4 mutation hotspots were screened by Sanger sequencing. Results: The authors detected neither heterozygous mutations nor homozygous mutations in exon 2, 8, 9, and 11 of SMAD4 in 90 cases of serous ovarian cancer. However, they identified a single nucleotide polymorphism (SNP) (rs77389132) in the intron 2 regions and marched the ExAC website (http://exac.broadinstitute.org/) for the SNP at Chr18: 48573689 and allele is A/G. Conclusions: The mutational rate of exons 2, 8, 9, and 11 of SMAD4 in serous ovarian cancer may be rare in Chinese people with primary serous ovarian cancer. Therefore, Seeking SMAD4 mutation for ovarian cancer susceptible population and individual treatment still need further pursuing.
机译:目的:先前的研究表明患有血液癌患者的SMAD4突变。研究的目的是分析中国人中的SMAD4突变,初级浆液卵巢癌,并试图构建基因型和临床表型之间的相关性或临床病理学的参数;因此,探讨血液癌癌的个体治疗的精确通用理论。材料和方法:作者收集了90例浆液癌病例,患有病理学家鉴定的主要样品。从PARAFIM - 嵌入肿瘤组织中提取DNA。 Smad4突变热点的外显子2,8,9和11通过Sanger测序筛选。结果:在90例浆液卵巢癌中,作者检测到杂合突变和外显子2,8,9和11中的纯合突变。然而,它们在Intron 2地区鉴定了单个核苷酸多态性(SNP)(RS77389132),并为SNP进行了SNP的EXAC网站(http://exac.broadinstitue.org/),在CHR18:48573689,​​等位基因是A / g。结论:血液癌中血液癌中的外显子2,8,9和11的突变率可能是初级浆液癌的中国人群。因此,寻求卵巢癌易感人群和个体治疗的Smad4突变仍需要进一步追求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号